Načítá se...
149. Effect of Lurasidone on Quality of Life, Function, and Metabolic Parameters in Adolescent Patients With Schizophrenia: Results From a 6-Week, Double-Blind, Placebo-Controlled Study
Background: Several atypical antipsychotics are approved to treat adolescent patients with schizophrenia. However, risk for antipsychotic-associated weight gain and metabolic dysfunction underscores the need to identify additional evidence-based treatments that are both efficacious and well tolerate...
Uloženo v:
| Vydáno v: | Schizophr Bull |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5475665/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbx021.207 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|